NO20044915L - C-aryl-glukosid SGLT2 inhibitorer og metode - Google Patents

C-aryl-glukosid SGLT2 inhibitorer og metode

Info

Publication number: NO20044915L
Authority: NO; Norway
Prior art keywords: aryl; sglt2 inhibitors; glucoside sglt2; glucoside; inhibitors
Prior art date: 2002-05-20

Application number

NO20044915A

Other languages

English (en)

Other versions

NO329107B1 (no

Inventor

Philip M Sher

William N Washburn

Bruce Ellsworth

Wei Meng

Gang Wu

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-20

Filing date

2004-11-11

Publication date

2004-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29582046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20044915(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-12-16 Publication of NO20044915L publication Critical patent/NO20044915L/no

2010-08-23 Publication of NO329107B1 publication Critical patent/NO329107B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20044915A 2002-05-20 2004-11-11 C-arylglukosider, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom NO329107B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/151,436 US6515117B2 (en)	1999-10-12	2002-05-20	C-aryl glucoside SGLT2 inhibitors and method
PCT/US2003/015591 WO2003099836A1 (en)	2002-05-20	2003-05-15	C-aryl glucoside sglt2 inhibitors and method

Publications (2)

Publication Number	Publication Date
NO20044915L true NO20044915L (no)	2004-12-16
NO329107B1 NO329107B1 (no)	2010-08-23

Family

ID=29582046

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20044915A NO329107B1 (no)	2002-05-20	2004-11-11	C-arylglukosider, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom
NO2013007C NO2013007I1 (no)	2002-05-20	2013-04-12	Dapagliflozin og farmasøytisk akseptable salter derav
NO2014017C NO2014017I1 (no)	2002-05-20	2014-07-09	En kombinasjon av dapagliflozin eller et farmasøytisk akseptabelt salt derav og metformin eller et farmasøytisk akseptabelt salt derav
NO2022041C NO2022041I1 (no)	2002-05-20	2022-10-03	Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO2013007C NO2013007I1 (no)	2002-05-20	2013-04-12	Dapagliflozin og farmasøytisk akseptable salter derav
NO2014017C NO2014017I1 (no)	2002-05-20	2014-07-09	En kombinasjon av dapagliflozin eller et farmasøytisk akseptabelt salt derav og metformin eller et farmasøytisk akseptabelt salt derav
NO2022041C NO2022041I1 (no)	2002-05-20	2022-10-03	Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC

Country Status (39)

Country	Link
US (1)	US6515117B2 (no)
EP (1)	EP1506211B1 (no)
JP (4)	JP5090621B2 (no)
KR (1)	KR101021752B1 (no)
CN (5)	CN104230866A (no)
AR (1)	AR040032A1 (no)
AT (1)	ATE353334T1 (no)
AU (1)	AU2003237886B2 (no)
BE (2)	BE2013C025I2 (no)
BR (2)	BR122017015091B8 (no)
CA (1)	CA2486539C (no)
CY (3)	CY1106465T1 (no)
DE (1)	DE60311649T2 (no)
DK (1)	DK1506211T3 (no)
ES (1)	ES2280759T3 (no)
FR (2)	FR13C0022I2 (no)
GE (1)	GEP20084403B (no)
HK (2)	HK1068214A1 (no)
HR (1)	HRP20041084B1 (no)
IL (1)	IL165119A0 (no)
IN (1)	IN2004DE03573A (no)
IS (1)	IS7529A (no)
LT (1)	LTC1506211I2 (no)
LU (2)	LU92182I2 (no)
ME (2)	MEP13008A (no)
MX (1)	MX249731B (no)
MY (1)	MY142499A (no)
NO (4)	NO329107B1 (no)
NZ (1)	NZ536605A (no)
PE (1)	PE20040760A1 (no)
PL (1)	PL210304B1 (no)
PT (1)	PT1506211E (no)
RS (1)	RS51469B (no)
RU (4)	RU2337916C2 (no)
SI (1)	SI1506211T1 (no)
TW (1)	TWI310770B (no)
UA (1)	UA77306C2 (no)
WO (1)	WO2003099836A1 (no)
ZA (1)	ZA200409295B (no)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh) *	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
FR2809310B1 (fr) *	2000-05-26	2004-02-13	Centre Nat Rech Scient	Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
CA2430010A1 (en)	2000-11-30	2002-06-06	University Of Florida	Treatments for neurogenetic disorders, impulse control disorders, and wound healing
ATE430749T1 (de) *	2001-02-24	2009-05-15	Boehringer Ingelheim Pharma	Xanthinderivate verwendung als arzneimittel sowie deren verfahren zur deren herstellung
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
CA2442917C (en) *	2001-04-04	2011-02-01	Ortho-Mcneil Pharmaceutical, Inc.	Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
ATE318272T1 (de) *	2001-04-11	2006-03-15	Bristol Myers Squibb Co	Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
WO2003020737A1 (en) *	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
TWI254635B (en) *	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
US7407955B2 (en) *	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1550668A4 (en) *	2002-10-04	2008-10-01	Kissei Pharmaceutical	PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION COMPRISING THE DERIVATIVE, MEDICINAL USE THEREOF, AND INTERMEDIATE ENTERING THE PRODUCTION THEREOF
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2512389A1 (en) *	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
EP1457206A1 (en) *	2003-03-13	2004-09-15	Fournier Laboratories Ireland Limited	Combined use of a fibrate and orlistat for the treatment of obesity
WO2004080990A1 (ja)	2003-03-14	2004-09-23	Astellas Pharma Inc.	Ｃ－グリコシド誘導体又はその塩
JP2004300102A (ja) *	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP4130466B2 (ja) *	2003-08-01	2008-08-06	田辺三菱製薬株式会社	新規化合物
RS20060320A (en) *	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Substituted indazole-o-glucosides
TW200521131A (en) *	2003-08-01	2005-07-01	Janssen Pharmaceutica Nv	Substituted fused heterocyclic c-glycosides
US7094764B2 (en) *	2003-08-01	2006-08-22	Janssen Pharmaceutica N.V.	Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
US8785403B2 (en) *	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
US7129220B2 (en) *	2003-08-01	2006-10-31	Janssen Pharmaceutica N.V	Substituted indole-O-glucosides
US7371759B2 (en) *	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en) *	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
RU2387663C2 (ru) *	2004-03-04	2010-04-27	Киссеи Фармасьютикал Ко., Лтд.	Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
WO2005092877A1 (de)	2004-03-16	2005-10-06	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US7393836B2 (en) *	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004034690A1 (de) *	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) *	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
CA2574451A1 (en) *	2004-07-27	2006-02-02	Boehringer Ingelheim International Gmbh	D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
EP1803729A4 (en) *	2004-09-29	2008-10-01	Kissei Pharmaceutical	HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1807093A2 (en) *	2004-10-13	2007-07-18	Isis Pharmaceuticals, Inc.	Antisense modulation of ptp1b expression
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006064033A2 (en) *	2004-12-16	2006-06-22	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
MY147375A (en) *	2005-01-31	2012-11-30	Mitsubishi Tanabe Pharma Corp	Indole derivatives
ES2319461T3 (es) *	2005-02-10	2009-05-07	Bristol-Myers Squibb Company	Dihidroquinazolinonas como moduladores de 5ht.
ATE445608T1 (de) *	2005-02-23	2009-10-15	Boehringer Ingelheim Int	Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
WO2006108842A1 (en) *	2005-04-15	2006-10-19	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7723309B2 (en) *	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) *	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) *	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) *	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
TW200733966A (en) *	2005-07-27	2007-09-16	Boehringer Ingelheim Int	Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN101268075A (zh) *	2005-07-28	2008-09-17	百时美施贵宝公司	作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7795436B2 (en) *	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
JP5175191B2 (ja) *	2005-08-30	2013-04-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
DE602006018961D1 (de) *	2005-09-08	2011-01-27	Boehringer Ingelheim Pharma	KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG
AR056195A1 (es) *	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
KR20080081354A (ko) *	2005-12-28	2008-09-09	다케다 야쿠힌 고교 가부시키가이샤	당뇨병 치료제
AR059489A1 (es)	2006-02-15	2008-04-09	Boehringer Ingelheim Vetmed	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080697A1 (es) *	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es) *	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
WO2007143052A1 (en) *	2006-06-01	2007-12-13	Glycomimetics, Inc.	Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) *	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en)	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI418556B (zh) *	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
TWI403516B (zh)	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh)	2006-07-27	2014-04-01	Chugai Pharmaceutical Co Ltd	稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
EP2054426A1 (en)	2006-08-15	2009-05-06	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
EP2066344B2 (en) *	2006-09-07	2016-06-29	GlaxoSmithKline Biologicals S.A.	Inactivated Poliovirus combination vaccine
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
US20080194575A1 (en) *	2006-10-04	2008-08-14	Naiara Beraza	Treatment for non-alcoholic-steatohepatitis
MX2009003927A (es)	2006-10-13	2009-04-23	Chugai Pharmaceutical Co Ltd	Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
CA2667550A1 (en)	2006-10-27	2008-05-02	Boehringer Ingelheim International Gmbh	Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UY30730A1 (es) *	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5298025B2 (ja) *	2006-12-04	2013-09-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体
KR20090097184A (ko)	2006-12-06	2009-09-15	스미스클라인 비참 코포레이션	비시클릭 화합물 및 항당뇨병제로서의 용도
EP2105442A4 (en)	2006-12-21	2013-01-23	Astellas Pharma Inc	PROCESS FOR PREPARING A C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE PRODUCT THEREFOR
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
PE20090185A1 (es) *	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2014201239B2 (en) *	2007-03-22	2016-03-10	Astrazeneca Ab	Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
TW200904454A (en) *	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090696A1 (es) *	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en)	2007-06-04	2020-10-20	Kunwar Shailubhai	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
DK2183263T3 (da) *	2007-07-26	2012-01-30	Lexicon Pharmaceuticals Inc	Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
PE20090603A1 (es) *	2007-08-16	2009-06-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
CL2008002427A1 (es) *	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
MX2010001821A (es) *	2007-08-17	2010-03-10	Boehringer Ingelheim Int	Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
EP3318562A3 (en) *	2007-08-23	2018-09-12	Theracos Sub, LLC	Benzylbenzene derivatives and methods of use
NO2200606T3 (no)	2007-09-10	2018-03-24
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
EP2217602B1 (en) *	2007-11-30	2018-08-29	Boehringer Ingelheim International GmbH	1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) *	2007-12-27	2015-03-04	阿斯利康公司	Sglt2 抑制剂的晶体结构及其制备方法
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
JP5302900B2 (ja) *	2008-01-31	2013-10-02	アステラス製薬株式会社	脂肪性肝疾患の治療用医薬組成物
CN101503399B (zh) *	2008-02-04	2012-06-27	白鹭医药技术（上海）有限公司	C-芳基葡萄糖苷sglt2抑制剂
UA105362C2 (en) *	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
WO2009143010A1 (en) *	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
WO2009143021A1 (en) *	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
ES2526930T3 (es)	2008-05-22	2015-01-16	Astrazeneca Ab	Método para el tratamiento de la hiperuricemia empleando un inhibidor de SGLT2 y composición que contiene el mismo
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2312944B1 (en) *	2008-07-15	2018-09-05	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
WO2010009319A2 (en)	2008-07-16	2010-01-21	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) *	2008-08-14	2011-08-04	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
CA2734295C (en)	2008-08-22	2016-12-20	Theracos, Inc.	Processes for the preparation of sglt2 inhibitors
WO2010023594A1 (en) *	2008-08-28	2010-03-04	Pfizer Inc.	Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
EP2334684B1 (en)	2008-09-08	2017-08-02	Boehringer Ingelheim International GmbH	Pyrazolopyrimidines and their use for the treatment of cns disorders
MX2011002558A (es)	2008-09-10	2011-04-26	Boehringer Ingelheim Int	Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20110230403A1 (en) *	2008-09-19	2011-09-22	Novartis Ag	Glycoside derivatives and uses thereof
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010045656A2 (en) *	2008-10-17	2010-04-22	Nectid, Inc.	Novel sglt2 inhibitor dosage forms
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
AU2009331471B2 (en)	2008-12-23	2015-09-03	Boehringer Ingelheim International Gmbh	Salt forms of organic compound
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EA024072B1 (ru) *	2009-02-13	2016-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
CN102316875A (zh)	2009-02-13	2012-01-11	贝林格尔.英格海姆国际有限公司	用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
CA2751834C (en)	2009-02-13	2018-07-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
ES2397086T3 (es) *	2009-02-23	2013-03-04	Taisho Pharmaceutical Co., Ltd.	Compuestos de 4-isopropilfenil glucitol como inhibidores de SGLT1
EP2226076A1 (de)	2009-02-25	2010-09-08	Henning Vollert	Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
EP2414363B1 (en) *	2009-03-31	2014-01-08	Boehringer Ingelheim International GmbH	1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
JP2012528170A (ja) *	2009-05-27	2012-11-12	ブリストル−マイヤーズスクイブカンパニー	別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
CA2767258C (en)	2009-07-10	2016-09-13	Janssen Pharmaceutica Nv	Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
TW201118099A (en) *	2009-08-12	2011-06-01	Boehringer Ingelheim Int	New compounds for the treatment of CNS disorders
DK2486029T3 (en)	2009-09-30	2015-08-24	Boehringer Ingelheim Int	Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
PH12012500633B1 (en) *	2009-09-30	2017-12-13	Boehringer Ingelheim Int	Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
UY32919A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112012008939B1 (pt) *	2009-10-14	2021-06-22	Janssen Pharmaceutica Nv	Processo para a preparação de compostos úteis como inibidores de sglt2
US8163704B2 (en) *	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
DK2496583T3 (en)	2009-11-02	2015-02-02	Pfizer	Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
EP2498758B1 (en) *	2009-11-13	2018-07-25	AstraZeneca AB	Bilayer tablet formulations
AU2010319377B2 (en)	2009-11-13	2014-10-23	Astrazeneca Ab	Immediate release tablet formulations
CN102812011A (zh)	2009-11-16	2012-12-05	梅利科技公司	[1,5]-二氮杂环辛间四烯衍生物
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AR079438A1 (es)	2009-12-09	2012-01-25	Panacea Biotec Ltd	Derivados de azucar, composiciones farmaceuticas y sus usos
CN102134226B (zh) *	2010-01-26	2013-06-12	天津药物研究院	一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523681A (ja) *	2010-03-30	2013-06-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
MX366325B (es)	2010-05-05	2019-07-05	Boehringer Ingelheim Int	Terapia de combinacion.
MX339570B (es)	2010-05-11	2016-05-31	Janssen Pharmaceutica Nv	Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
EP2568971B1 (en)	2010-05-11	2020-10-14	Mitsubishi Tanabe Pharma Corporation	Canagliflozin containing tablets
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
EP3366304B1 (en)	2010-06-24	2020-05-13	Boehringer Ingelheim International GmbH	Diabetes therapy
KR101918909B1 (ko)	2010-08-12	2018-11-15	베링거 인겔하임 인터내셔날 게엠베하	６사이클로알킬１，５디하이드로피라졸로［３，４ｄ］피리미딘４온 유도체 및 이의 ｐｄｅ９ａ 억제제로서의 용도
WO2012025857A1 (en)	2010-08-23	2012-03-01	Hetero Research Foundation	Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US20130224296A1 (en)	2010-09-03	2013-08-29	Bristol-Myers Squibb Company	Drug Formulations Using Water Soluble Antioxidants
WO2012037034A1 (en)	2010-09-14	2012-03-22	Glycomimetics, Inc.	E-selectin antagonists
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en)	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh)	2010-10-27	2012-05-16	上海艾力斯医药科技有限公司	C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
TWI631963B (zh) *	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru)	2011-02-01	2017-01-10	Бристол-Майерс Сквибб Компани	Фармацевтические композиции, содержащие аминосоединение
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2676965B1 (en) *	2011-02-18	2017-10-04	Shanghai Yingli Pharmaceutical Co., Ltd	Aryl glycoside compound, preparation method and use thereof
CN102167715B (zh) *	2011-03-07	2013-04-24	上海惠斯生物科技有限公司	一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
DK2697218T3 (en)	2011-04-13	2016-07-25	Janssen Pharmaceutica Nv	PROCESS FOR THE PREPARATION OF COMPOUNDS useful as inhibitors of SGLT2
EP2703396B1 (en) *	2011-04-25	2016-06-22	Beijing Prelude Pharm. Sci.& Tech. Co., Ltd.	Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
CN104909997B (zh) *	2011-05-26	2017-04-12	Tf化学公司	芳基、杂芳基、o‑芳基和o‑杂芳基碳环糖家族
EP2529742B1 (en)	2011-06-03	2013-11-20	ratiopharm GmbH	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
WO2012163990A1 (en)	2011-06-03	2012-12-06	Boehringer Ingelheim International Gmbh	Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
EP2714049A1 (en)	2011-06-03	2014-04-09	Ratiopharm GmbH	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2725031B1 (en)	2011-06-25	2016-08-03	Xuanzhu Pharma Co., Ltd.	C-glycoside derivatives
US20130035298A1 (en)	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
PL3517539T3 (pl)	2011-07-15	2023-04-24	Boehringer Ingelheim International Gmbh	Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
WO2013038429A2 (en)	2011-09-13	2013-03-21	Panacea Biotec Ltd.	Novel sglt inhibitors
EP2773359A4 (en) *	2011-10-31	2015-10-21	Scinopharm Taiwan Ltd	CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS
EP2597090A1 (en)	2011-11-28	2013-05-29	Sandoz AG	Crystalline dapagliflozin hydrate
ES2655443T7 (es)	2011-12-22	2021-03-22	Glycomimetics Inc	Compuestos antagonistas de E-selectina
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103450214B (zh) *	2012-05-29	2016-04-06	广东东阳光药业有限公司	吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
EP3549587A1 (de)	2012-06-30	2019-10-09	BioActive Food GmbH	Zusammensetzung zur behandlung von hyperglykämischen erkrankungen
BR112015004012A2 (pt)	2012-08-30	2017-07-04	Taisho Pharmaceutical Co Ltd	combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
SI2928476T1 (en)	2012-12-07	2018-06-29	Glycomimetics, Inc.	COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
CN103910769B (zh)	2012-12-31	2018-10-02	上海璎黎药业有限公司	葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de)	2013-03-04	2016-05-18	BioActive Food GmbH	Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
PT3466431T (pt)	2013-03-14	2024-01-26	Msd Int Gmbh	Formas cristalinas e métodos para preparação de inibidores de sglt2
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
ES2959444T3 (es)	2013-04-04	2024-02-26	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de trastornos metabólicos en animales equinos
ES2702174T3 (es)	2013-04-05	2019-02-27	Boehringer Ingelheim Int	Usos terapéuticos de empagliflozina
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
MX381599B (es)	2013-04-18	2025-03-12	Boehringer Ingelheim Int Gmbh	Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria
EP2991999B1 (en)	2013-04-29	2019-05-08	Mapi Pharma Limited	Dapagliflozin lactose co-crystal
KR102272746B1 (ko)	2013-06-05	2021-07-08	보슈 헬스 아일랜드 리미티드	구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015040571A1 (en)	2013-09-23	2015-03-26	Ranbaxy Laboratories Limited	Process for the preparation of dapagliflozin
EP3049397A1 (en) *	2013-09-27	2016-08-03	Sun Pharmaceutical Industries Ltd	Process for the purification of dapagliflozin
WO2015043511A1 (en)	2013-09-27	2015-04-02	Sunshine Lake Pharma Co., Ltd.	Glucopyranosyl derivatives and their uses in medicine
WO2015051484A1 (en)	2013-10-12	2015-04-16	Theracos, Inc.	Preparation of hydroxy-benzylbenzene derivatives
EP3063116A1 (en)	2013-10-31	2016-09-07	Sun Pharmaceutical Industries Ltd	Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
WO2015091313A1 (en)	2013-12-17	2015-06-25	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in feline animals
US9902751B2 (en)	2013-12-30	2018-02-27	Mylan Laboratories Limited	Process for the preparation of empagliflozin
US9315438B2 (en)	2014-01-03	2016-04-19	Xuanzhu Pharma Co., Ltd	Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CN106349201B (zh) *	2014-01-03	2018-09-18	山东轩竹医药科技有限公司	光学纯的苄基-4-氯苯基的c-糖苷衍生物
CN103739581B (zh) *	2014-01-23	2016-11-23	中国药科大学	C-芳基葡萄糖苷sglt2抑制剂
WO2015110402A1 (en)	2014-01-23	2015-07-30	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in canine animals
CN104829572B (zh) *	2014-02-10	2019-01-04	江苏豪森药业集团有限公司	达格列净新晶型及其制备方法
IN2014MU00626A (no) *	2014-02-21	2015-09-25	Cadila Healthcare Ltd
US20170056365A1 (en)	2014-02-28	2017-03-02	Sun Pharmaceutical Industries Limited	Dapagliflozin compositions
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
US20170029398A1 (en)	2014-03-06	2017-02-02	Srinivasan Thirumalai Rajan	Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
AU2015239655B2 (en)	2014-04-01	2019-10-24	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in equine animals
CN105001213B (zh) *	2014-04-14	2020-08-28	上海迪诺医药科技有限公司	C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2944311A1 (de)	2014-05-16	2015-11-18	BioActive Food GmbH	Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
JP2017515908A (ja) *	2014-05-16	2017-06-15	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	Ｓｇｌｔ２インヒビター誘発性グルカゴン分泌の抑制方法
WO2015198227A1 (en)	2014-06-23	2015-12-30	Sun Pharmaceutical Industries Limited	Co-crystal of dapagliflozin with citric acid
ES2991763T3 (es)	2014-09-25	2024-12-04	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
MX2017003944A (es)	2014-09-25	2017-06-26	Astrazeneca Ab	Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
CN104327027B (zh) *	2014-10-14	2017-04-05	中国药科大学	一类新型c‑芳基葡萄糖苷sglt2抑制剂
CN104478839A (zh) *	2014-11-24	2015-04-01	苏州乔纳森新材料科技有限公司	一种达格列净的合成方法
CN104496952B (zh) *	2014-11-28	2017-04-19	深圳翰宇药业股份有限公司	一种达格列净的合成方法
CN107108679B (zh)	2014-12-03	2020-10-23	糖模拟物有限公司	E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CN105753910A (zh) *	2014-12-16	2016-07-13	康普药业股份有限公司	一种卡格列净中间体的制备方法
CN104529970A (zh) *	2015-01-08	2015-04-22	江苏联环药业股份有限公司	制备达格列净的方法
CN104478957A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104478968A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478959A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104530149A (zh) *	2015-01-14	2015-04-22	佛山市赛维斯医药科技有限公司	卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478966A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478965A (zh) *	2015-01-15	2015-04-01	佛山市赛维斯医药科技有限公司	一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497070A (zh) *	2015-01-15	2015-04-08	佛山市赛维斯医药科技有限公司	一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
CN104478963A (zh) *	2015-01-15	2015-04-01	佛山市赛维斯医药科技有限公司	一种含腈基苯s-葡萄糖苷结构的化合物及其用途
WO2016128995A1 (en)	2015-02-09	2016-08-18	Indoco Remedies Limited	Process for the preparation of sglt inhibitor compounds
BR112017019170A2 (pt)	2015-03-09	2018-07-10	Intekrin Therapeutics, Inc.	métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
WO2016161995A1 (en)	2015-04-08	2016-10-13	Zentiva, K.S.	Solid forms of amorphous dapagliflozin
WO2016178148A1 (en) *	2015-05-05	2016-11-10	Glenmark Pharmaceuticals Limited	Process for preparation of dapagliflozin
CN106317068A (zh) *	2015-06-23	2017-01-11	中国科学院上海药物研究所	一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN104961715B (zh) *	2015-07-10	2017-08-22	浙江美诺华药物化学有限公司	一种达格列净的制备方法
EP3349762B1 (en)	2015-09-15	2021-08-25	Laurus Labs Limited	Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CZ2015729A3 (cs)	2015-10-13	2017-04-26	Zentiva, K.S.	Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN105218329B (zh) *	2015-10-15	2017-05-03	上海应用技术学院	一种列净类似物中间体及其制备方法
WO2017064193A1 (en)	2015-10-15	2017-04-20	Boehringer Ingelheim International Gmbh	Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
US9845303B2 (en)	2015-10-19	2017-12-19	Cadila Healthcare Limited	Process for the preparation of dapagliflozin
CN106892929B (zh) *	2015-12-17	2020-01-14	上海艾力斯医药科技有限公司	螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) *	2015-12-28	2016-06-22	南昌大学	一种抗糖尿病化合物及其制备方法和用途
HUE051212T2 (hu) *	2016-01-04	2021-03-01	Jeil Pharmaceutical Co Ltd	Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
WO2017118945A1 (en)	2016-01-08	2017-07-13	Lupin Limited	Premix of dapagliflozin and process for the preparation thereof
CA3009836A1 (en)	2016-01-22	2017-07-27	Glycomimetics, Inc.	Glycomimetic inhibitors of pa-il and pa-iil lectins
US9834533B2 (en) *	2016-02-19	2017-12-05	Scinopharm Taiwan, Ltd.	Process for preparing SGLT2 inhibitors and intermediates thereof
US11291678B2 (en)	2016-03-02	2022-04-05	Glycomimetics, Inc	Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
BR112018069782A2 (pt)	2016-03-31	2019-01-29	Lupin Ltd	composição farmacêutica de dapagliflozina
CN107304194A (zh) *	2016-04-20	2017-10-31	扬子江药业集团上海海尼药业有限公司	制备达格列净的方法
ES2864153T3 (es) *	2016-05-24	2021-10-13	Jiangsu Hansoh Pharmaceutical Group Co Ltd	Nueva forma de cristal de dapagliflozina y método de preparación y uso de la misma
WO2017203229A1 (en)	2016-05-27	2017-11-30	Cipla Limited	Dapagliflozin premixes
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
JP2019524791A (ja)	2016-08-08	2019-09-05	グリコミメティクス，インコーポレイテッド	Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
EP3497090B1 (en) *	2016-08-09	2022-08-03	Laurus Labs Limited	Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
WO2018029264A1 (en)	2016-08-10	2018-02-15	Amneal Pharmaceuticals Company Gmbh	Process for preparation of dapagliflozin and intermediates thereof
US11072625B2 (en)	2016-10-07	2021-07-27	Glycomimetics, Inc.	Highly potent multimeric e-selectin antagonists
MX2019004549A (es)	2016-10-19	2019-06-12	Boehringer Ingelheim Int	Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
KR20180058510A (ko)	2016-11-24	2018-06-01	한미약품 주식회사	다파글리플로진 l-프롤린을 포함하는 약제학적 제제
CN108218928B (zh) *	2016-12-13	2020-06-30	华润双鹤药业股份有限公司	葡萄糖苷的二环衍生物及其制备方法和用途
WO2018142422A1 (en) *	2017-02-02	2018-08-09	Indoco Remedies Limited	Process for the preparation of dapagliflozin
JP7272956B2 (ja)	2017-03-15	2023-05-12	グリコミメティクス，インコーポレイテッド	Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11020412B2 (en)	2017-03-16	2021-06-01	Inventia Healthcare Limited	Pharmaceutical composition comprising dapagliflozin
CN110996951A (zh)	2017-04-03	2020-04-10	科赫罗斯生物科学股份有限公司	治疗进行性核上性麻痹的PPARγ激动剂
WO2018207111A1 (en)	2017-05-09	2018-11-15	Piramal Enterprises Limited	A process for the preparation of sglt2 inhibitors and intermediates thereof
AR112015A1 (es)	2017-06-09	2019-09-11	Novo Nordisk As	Composiciones sólidas para administración oral
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
EA202091324A1 (ru) *	2017-11-30	2020-10-05	Идорсия Фармасьютиклз Лтд	Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
WO2019108750A1 (en)	2017-11-30	2019-06-06	Glycomimetics, Inc.	Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh)	2017-12-29	2020-08-21	糖模拟物有限公司	E-选择蛋白和半乳凝素-3的异双功能抑制剂
CN111867601A (zh)	2018-03-05	2020-10-30	糖模拟物有限公司	用于治疗急性髓系白血病及相关病症的方法
AU2019254371A1 (en)	2018-04-17	2020-10-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
KR102204439B1 (ko)	2018-05-14	2021-01-18	에이치케이이노엔 주식회사	Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
EP3810623A1 (en)	2018-06-25	2021-04-28	Pharmathen S.A.	A novel process for the preparation of sglt-2 inhibitors
CA3105626A1 (en) *	2018-07-19	2020-01-23	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
KR102131359B1 (ko)	2018-09-07	2020-07-07	오토텔릭바이오 주식회사	안정성이 향상된 의약 조성물
JP7425793B2 (ja)	2018-10-29	2024-01-31	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CA3112510A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109705075B (zh) *	2018-12-13	2022-12-23	苏中药业集团股份有限公司	一种达格列净的纯化方法
US11845771B2 (en)	2018-12-27	2023-12-19	Glycomimetics, Inc.	Heterobifunctional inhibitors of E-selectin and galectin-3
JOP20200098A1 (ar)	2019-08-30	2021-02-28	Astrazeneca Ab	طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
UY38969A (es) *	2019-11-28	2021-05-31	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
BR112022016360A2 (pt)	2020-02-17	2022-10-04	Boehringer Ingelheim Vetmedica Gmbh	Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
WO2021165316A1 (en)	2020-02-21	2021-08-26	Zakłady Farmaceutyczne POLPHARMA S.A.	Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en)	2020-03-05	2021-09-10	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising sglt2 inhibitor
TWI865738B (zh)	2020-03-06	2024-12-11	美商維泰克斯製藥公司	治療apol-1依賴性局灶性節段性腎小球硬化之方法
CA3180674A1 (en)	2020-04-22	2021-10-28	Bayer Aktiengesellschaft	Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20230165856A1 (en)	2020-04-29	2023-06-01	Astrazeneca Ab	Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
EP4161912A1 (en)	2020-06-05	2023-04-12	KRKA, d.d., Novo mesto	Preparation of highly pure amorphous dapagliflozin
WO2021260617A1 (en) *	2020-06-25	2021-12-30	Hikal Limited	An improved process for preparation of dapagliflozin propanediol monohydrate
CA3188345A1 (en)	2020-07-10	2022-01-13	Astrazeneca Ab	Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
TW202220672A (zh)	2020-07-27	2022-06-01	瑞典商阿斯特捷利康公司	用達格列淨治療慢性腎臟病之方法
WO2022051316A1 (en)	2020-09-03	2022-03-10	Coherus Biosciences, Inc.	Fixed dose combinations of chs-131 and a sglt-2 inhibitor
EP4206212A4 (en)	2020-09-30	2024-05-22	Beijing Creatron Institute of Pharmaceutical Research Co., Ltd.	SGLT-2 AND SARCOSINE INHIBITOR COCRYSTAL, PROCESS FOR PREPARATION THEREFOR AND USE THEREOF
TR202019589A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
TR202019592A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Amorf dapagliflozinin katı farmasötik formülasyonları
WO2022119543A1 (en)	2020-12-03	2022-06-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR202019590A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
AU2022251165A1 (en)	2021-04-01	2023-11-09	Astrazeneca Uk Limited	Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
EP4079296A1 (en)	2021-04-21	2022-10-26	Sanovel Ilac Sanayi Ve Ticaret A.S.	A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
MX2024001184A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
US20240269105A1 (en)	2021-07-28	2024-08-15	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CA3224673A1 (en)	2021-07-28	2023-02-02	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
CN113773194B (zh)	2021-08-16	2023-05-02	浙江奥翔药业股份有限公司	作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
IL314031A (en)	2021-12-30	2024-09-01	Newamsterdam Pharma B V	Materials and methods for improved phosphotransferases
EP4212150A1 (en)	2022-01-13	2023-07-19	Sanovel Ilac Sanayi Ve Ticaret A.S.	A bilayer tablet composition comprising amorphous dapagliflozin and metformin
CN118510504A (zh)	2022-01-26	2024-08-16	阿斯利康(瑞典)有限公司	用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
US20230381101A1 (en)	2022-05-25	2023-11-30	Boehringer Ingelheim Vetmedica Gmbh	Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
TW202415364A (zh)	2022-06-07	2024-04-16	瑞典商阿斯特捷利康公司	Ｒｘｆｐ１調節劑和ｓｇｌｔ２抑制劑之組合
KR102490653B1 (ko) *	2022-08-03	2023-01-20	진양제약주식회사	다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
KR20240028315A (ko)	2022-08-24	2024-03-05	주식회사 제뉴원사이언스	다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
WO2024166009A1 (en)	2023-02-08	2024-08-15	Astrazeneca Ab	Combination of zibotentan and dapagliflozin for the treatment of high proteinuria chronic kidney disease
EP4427742A1 (en)	2023-03-06	2024-09-11	Galenicum Health S.L.U.	Pharmaceutical compositions comprising dapagliflozin and metformin
US20240307628A1 (en)	2023-03-06	2024-09-19	Boehringer Ingelheim Vetmedica Gmbh	Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
EP4431088A1 (en)	2023-03-06	2024-09-18	Galenicum Health S.L.U.	Pharmaceutical compositions comprising dapagliflozin and metformin
WO2024226537A1 (en)	2023-04-24	2024-10-31	Newamsterdam Pharma B.V.	Amorphous obicetrapib and sglt2 inhibitor combination
US20240390332A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
US20240390317A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
EP4487910A1 (en)	2023-07-06	2025-01-08	Zaklady Farmaceutyczne Polpharma S.A.	Process for the preparation of dapagliflozin
CN118908926A (zh) *	2024-07-24	2024-11-08	安徽海康药业股份有限公司	一种达格列净的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU1088346A1 (ru) *	1982-09-28	1986-12-30	Тихоокеанский институт биоорганической химии Дальневосточного научного центра АН СССР	Ацетилированные гликозиды 2,5- и 2,8 -дигидрокси-1,4-нафтохинонов,обладающие антигрибковой активностью
JPH03133746A (ja) *	1989-10-19	1991-06-06	Taiyo Kagaku Kogyo Kk	自立袋およびその製造方法
CA2102591C (en)	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
EP0671953A4 (en) *	1992-11-13	1996-01-10	Univ Ohio State Res Found	C-GLYCOSIDE ANALOG OF N- (HYDROXYPHENYL) RETINAMIDE-O-GLUCURONID.
US5444050A (en) *	1994-04-29	1995-08-22	Texas Biotechnology Corporation	Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja)	1994-05-11	1998-10-27	田辺製薬株式会社	血糖降下剤
US5830873A (en)	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
JP3034192B2 (ja)	1995-11-07	2000-04-17	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
JP3006513B2 (ja)	1995-11-07	2000-02-07	田辺製薬株式会社	医薬組成物
JP3059088B2 (ja)	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
EP0850948B1 (en)	1996-12-26	2002-04-24	Tanabe Seiyaku Co., Ltd.	Propiophenone derivatives and process for preparing the same
WO1998031697A1 (en)	1997-01-15	1998-07-23	Sankyo Company, Limited	Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja)	1997-03-03	1998-09-14	Dainippon Ink & Chem Inc	７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
USRE39072E1 (en) *	1997-04-04	2006-04-18	Mitsubishi Pharma Corporation	2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JP3451000B2 (ja)	1997-10-20	2003-09-29	新日本製鐵株式会社	方向性珪素鋼板の絶縁皮膜形成方法
DE19806803A1 (de) *	1998-02-18	1999-11-25	Hermann Koepsell	Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
GB9811427D0 (en) *	1998-05-29	1998-07-22	Zeneca Ltd	Chemical compounds
US6486299B1 (en)	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) *	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
ATE318272T1 (de) *	2001-04-11	2006-03-15	Bristol Myers Squibb Co	Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren

2002
- 2002-05-20 US US10/151,436 patent/US6515117B2/en active Active
2003
- 2003-05-14 TW TW092113121A patent/TWI310770B/zh active
- 2003-05-15 CN CN201410345395.9A patent/CN104230866A/zh active Pending
- 2003-05-15 KR KR1020047018685A patent/KR101021752B1/ko active IP Right Review Request
- 2003-05-15 CN CN2009101586866A patent/CN101628905B/zh not_active Expired - Lifetime
- 2003-05-15 WO PCT/US2003/015591 patent/WO2003099836A1/en active IP Right Grant
- 2003-05-15 GE GEAP8537A patent/GEP20084403B/en unknown
- 2003-05-15 CN CNA2007101089864A patent/CN101092409A/zh active Pending
- 2003-05-15 DK DK03736643T patent/DK1506211T3/da active
- 2003-05-15 SI SI200330776T patent/SI1506211T1/sl unknown
- 2003-05-15 CN CNB038113538A patent/CN100534997C/zh not_active Expired - Lifetime
- 2003-05-15 ME MEP-130/08A patent/MEP13008A/xx unknown
- 2003-05-15 BR BR122017015091A patent/BR122017015091B8/pt active IP Right Grant
- 2003-05-15 NZ NZ536605A patent/NZ536605A/en not_active IP Right Cessation
- 2003-05-15 PT PT03736643T patent/PT1506211E/pt unknown
- 2003-05-15 ES ES03736643T patent/ES2280759T3/es not_active Expired - Lifetime
- 2003-05-15 UA UA20041210415A patent/UA77306C2/uk unknown
- 2003-05-15 RU RU2004137489/04A patent/RU2337916C2/ru not_active IP Right Cessation
- 2003-05-15 CA CA2486539A patent/CA2486539C/en not_active Expired - Lifetime
- 2003-05-15 AT AT03736643T patent/ATE353334T1/de active
- 2003-05-15 DE DE60311649T patent/DE60311649T2/de not_active Expired - Lifetime
- 2003-05-15 EP EP03736643A patent/EP1506211B1/en not_active Expired - Lifetime
- 2003-05-15 AU AU2003237886A patent/AU2003237886B2/en active Active
- 2003-05-15 BR BRPI0311323A patent/BRPI0311323B8/pt active IP Right Grant
- 2003-05-15 ME MEP-2008-130A patent/ME00091B/me unknown
- 2003-05-15 CN CN201210054766.9A patent/CN102627676B/zh not_active Expired - Lifetime
- 2003-05-15 PL PL373369A patent/PL210304B1/pl unknown
- 2003-05-15 RS YUP-992/04A patent/RS51469B/en unknown
- 2003-05-15 JP JP2004507493A patent/JP5090621B2/ja not_active Expired - Lifetime
- 2003-05-15 MX MXPA04011371 patent/MX249731B/es active IP Right Grant
- 2003-05-16 AR ARP030101713A patent/AR040032A1/es active IP Right Grant
- 2003-05-16 MY MYPI20031803A patent/MY142499A/en unknown
- 2003-05-20 PE PE2003000491A patent/PE20040760A1/es active IP Right Grant
2004
- 2004-11-09 IL IL16511904A patent/IL165119A0/xx active Protection Beyond IP Right Term
- 2004-11-11 NO NO20044915A patent/NO329107B1/no not_active IP Right Cessation
- 2004-11-16 IN IN3573DE2004 patent/IN2004DE03573A/en unknown
- 2004-11-16 IS IS7529A patent/IS7529A/is unknown
- 2004-11-18 HR HR20041084A patent/HRP20041084B1/xx not_active IP Right Cessation
- 2004-11-18 ZA ZA200409295A patent/ZA200409295B/xx unknown
2005
- 2005-03-08 HK HK05101975A patent/HK1068214A1/xx not_active IP Right Cessation
2007
- 2007-05-03 CY CY20071100584T patent/CY1106465T1/el unknown
2008
- 2008-06-06 RU RU2008122558A patent/RU2489151C3/ru active Protection Beyond IP Right Term
2009
- 2009-08-18 JP JP2009189324A patent/JP5340077B2/ja not_active Expired - Lifetime
2012
- 2012-07-19 JP JP2012160579A patent/JP5584738B2/ja not_active Expired - Lifetime
2013
- 2013-04-03 LT LTPA2013008C patent/LTC1506211I2/lt unknown
- 2013-04-04 FR FR13C0022C patent/FR13C0022I2/fr active Active
- 2013-04-08 RU RU2013115635A patent/RU2643764C9/ru active IP Right Revival
- 2013-04-09 BE BE2013C025C patent/BE2013C025I2/fr unknown
- 2013-04-10 CY CY2013013C patent/CY2013013I1/el unknown
- 2013-04-12 NO NO2013007C patent/NO2013007I1/no unknown
- 2013-04-17 LU LU92182C patent/LU92182I2/fr unknown
- 2013-08-02 JP JP2013161572A patent/JP5604568B2/ja not_active Expired - Lifetime
2014
- 2014-07-08 FR FR14C0054C patent/FR14C0054I1/fr active Active
- 2014-07-09 BE BE2014C041C patent/BE2014C041I2/fr unknown
- 2014-07-09 NO NO2014017C patent/NO2014017I1/no unknown
- 2014-07-10 LU LU92496C patent/LU92496I2/xx unknown
- 2014-07-11 CY CY2014025C patent/CY2014025I1/el unknown
2015
- 2015-06-19 HK HK15105854.7A patent/HK1205120A1/xx unknown
2017
- 2017-09-07 RU RU2017131447A patent/RU2017131447A/ru unknown
2022
- 2022-10-03 NO NO2022041C patent/NO2022041I1/no unknown

Also Published As

Publication number	Publication date
FR13C0022I2 (fr)	2014-03-07
SI1506211T1 (sl)	2007-10-31
US20020137903A1 (en)	2002-09-26
CY2013013I2 (el)	2015-11-04
RU2013115635A (ru)	2014-10-20
BRPI0311323B8 (pt)	2021-05-25
CN101092409A (zh)	2007-12-26
CY1106465T1 (el)	2012-01-25
BE2014C041I2 (no)	2022-08-09
JP2012207037A (ja)	2012-10-25
ES2280759T3 (es)	2007-09-16
RU2489151C3 (ru)	2019-11-28
CN104230866A (zh)	2014-12-24
CN102627676B (zh)	2014-08-20
MEP13008A (en)	2010-06-10
RU2643764C9 (ru)	2021-12-15
NZ536605A (en)	2007-05-31
NO2014017I1 (no)	2014-07-09
JP5340077B2 (ja)	2013-11-13
KR20050004161A (ko)	2005-01-12
HRP20041084B1 (en)	2008-06-30
AU2003237886A1 (en)	2003-12-12
CN102627676A (zh)	2012-08-08
JP5604568B2 (ja)	2014-10-08
LTPA2013008I1 (lt)	2013-05-27
NO329107B1 (no)	2010-08-23
BR0311323A (pt)	2005-03-15
WO2003099836A1 (en)	2003-12-04
NO2013007I1 (no)	2013-04-29
RS99204A (en)	2006-12-15
HK1068214A1 (en)	2005-04-22
LU92182I2 (fr)	2013-06-17
ATE353334T1 (de)	2007-02-15
KR101021752B1 (ko)	2011-03-15
MXPA04011371A (es)	2005-02-14
HK1205120A1 (en)	2015-12-11
BR122017015091B8 (pt)	2021-07-27
PL373369A1 (en)	2005-08-22
JP5584738B2 (ja)	2014-09-03
JP2014028807A (ja)	2014-02-13
RU2017131447A (ru)	2019-03-07
RU2643764C2 (ru)	2018-02-05
MX249731B (es)	2007-10-01
CY2013013I1 (el)	2015-11-04
LU92182I9 (no)	2019-01-04
MY142499A (en)	2010-11-30
IN2004DE03573A (no)	2005-04-01
EP1506211A4 (en)	2005-08-17
CN101628905A (zh)	2010-01-20
CA2486539A1 (en)	2003-12-04
RU2746132C1 (ru)	2021-04-07
IS7529A (is)	2004-11-16
JP5090621B2 (ja)	2012-12-05
RU2489151C2 (ru)	2013-08-10
CN1653075A (zh)	2005-08-10
TW200404813A (en)	2004-04-01
TWI310770B (en)	2009-06-11
RU2004137489A (ru)	2005-06-27
IL165119A0 (en)	2005-12-18
RU2746132C3 (ru)	2021-08-02
BE2013C025I2 (no)	2022-09-29
EP1506211A1 (en)	2005-02-16
CY2014025I2 (el)	2015-11-04
UA77306C2 (uk)	2006-11-15
AR040032A1 (es)	2005-03-09
BRPI0311323B1 (pt)	2017-09-26
CA2486539C (en)	2012-03-13
PL210304B1 (pl)	2011-12-30
RU2337916C2 (ru)	2008-11-10
FR13C0022I1 (fr)	2014-02-03
CY2014025I1 (el)	2015-11-04
ZA200409295B (en)	2006-02-22
DE60311649D1 (de)	2007-03-22
HRP20041084A2 (en)	2005-06-30
US6515117B2 (en)	2003-02-04
DK1506211T3 (da)	2007-04-10
NO2022041I1 (no)	2022-10-03
CN101628905B (zh)	2012-03-21
LTC1506211I2 (lt)	2023-02-10
JP2009275050A (ja)	2009-11-26
FR14C0054I1 (fr)	2014-08-08
GEP20084403B (en)	2008-06-25
CN100534997C (zh)	2009-09-02
AU2003237886B2 (en)	2009-02-05
RU2017131447A3 (no)	2021-01-14
RS51469B (en)	2011-04-30
JP2005531588A (ja)	2005-10-20
NO2013007I2 (no)	2013-04-12
PT1506211E (pt)	2007-04-30
BR122017015091B1 (pt)	2018-05-15
LU92496I2 (fr)	2014-09-10
ME00091B (me)	2010-10-10
PE20040760A1 (es)	2004-11-20
DE60311649T2 (de)	2007-11-22
EP1506211B1 (en)	2007-02-07
RU2008122558A (ru)	2009-12-20

Publication	Publication Date	Title
NO20044915L (no)	2004-12-16	C-aryl-glukosid SGLT2 inhibitorer og metode
NO20040640L (no)	2004-08-16	Anordning og fremgangsmate
NO20032220D0 (no)	2003-05-15	Löfteverktöy II og fremgangsmåte for anvendelse av samme
NO20014823L (no)	2001-10-04	Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
DE60319787D1 (de)	2008-04-30	Montageverfahren und -vorrichtung
NO20054453L (no)	2005-11-29	P38 inhibitorer og fremgangsmater for anvendelse derav
NO20042376L (no)	2004-08-03	Jordrensesystemer og fremgangsmater
DK1997809T3 (da)	2014-07-21	P38-inhibitorer og fremgangsmåder til anvendelse deraf
DK1592686T3 (da)	2009-10-19	Gyrase-inhibitorer og anvendelser deraf
NO20031776D0 (no)	2003-04-16	Null-boringskomplettering og produksjonssystem
DK1357025T3 (da)	2009-11-16	Skæreindretning og fremgangmåde til skæring
NO20026054D0 (no)	2002-12-17	Akustisk loggeapparat og fremgangsmåte
DK1601744T3 (da)	2012-08-20	Forgasningsapparat og fremgangsmåde
IS8489A (is)	2006-05-26	Umritunarstillar og aðferðir þeirra
NO20031378D0 (no)	2003-03-26	Gjengivelsesmetode, gjengivelsesanordning, registreringsmetode og registreringsanordning
NO20044848D0 (no)	2004-11-08	Anordning og fremgangsmate
NO20043708L (no)	2004-09-03	Fremgangsmate og anording for borekaksbehandling
FI20020162L (fi)	2003-07-30	Menetelmä ja laite kuumaliimaukseen
NO20014376D0 (no)	2001-09-07	Anordning, fremgangsmåte og anvendelse
DK1567603T3 (da)	2006-11-06	Fluidledning og fremgangsmåde dertil
NO20055668D0 (no)	2005-11-30	Beta-amyloidinhibitorer og anvendelse derav
FI20020901A (fi)	2003-11-14	Menetelmä kylmälaitteen yhteydessä ja kylmälaite
NO20031959L (no)	2004-11-01	System og fremgangsmate for stromsparing
NO20041050L (no)	2004-09-15	Fremgmgsmate og sammensetninger
NO20024817D0 (no)	2002-10-04	System og metode for fordamping

Legal Events

Date	Code	Title	Description
2013-04-29	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: FORXIGA INNEHOLDENDE DAGAPLIFLOZIN (RINN) SOM AKTIVT STOFF. DAGAPLIFLOZIN ER OMFATTET AV DEN GENERELLE STRUKTUREN ANGITT I KRAV 1; NAT. REG. NO/DATE: 001-01 20121206; FIRST REG. NO/DATE: EU/1/12/795/001-010 20121112 Spc suppl protection certif: 2013007 Filing date: 20130412
2014-05-12	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA AB, SE
2014-06-23	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: FORXIGA INNEHOLDENDE DAGAPLIFLOZIN (RINN) SOM AKTIVT STOFF. DAGAPLIFLOZIN ER OMFATTET AV DEN GENERELLE STRUKTUREN ANGITT I KRAV 1; NAT. REG. NO/DATE: EU/1/12/795/NO 001-01 20121206; FIRST REG. NO/DATE: EU/1/12/795/001-010 20121112 Spc suppl protection certif: 2013007 Filing date: 20130412 Extension date: 20271112
2016-02-01	SPCW	Withdrawal, rejection or dismissal of supplementary protection certificate	Free format text: PRODUCT NAME: XIGDUO - DAPAGLIFLOZIN/METFORMIN: REG. NO/DATE: NO, EU/1/13/900, 20140116 Spc suppl protection certif: 2014017
2017-07-10	SPCK	Change in the validity period of an spc	Free format text: PRODUCT NAME: DAPAGLIFLOZIN OG FARMASOEYTISK AKSEPTABLE SALTER DERAV Spc suppl protection certif: 2013007 Filing date: 20130412 Extension date: 20271114
2018-02-05	SPCA	Appeal filed to the court after rejection of an spc	Free format text: KLAGE PA PATENTSTYRETS AVGJOERELSE INNKOMMET: 2016.03.22 KLAGENEMNDAS AVGJOERELSE AV 2017.02.13: 1. KLAGEN FORKASTES. 2. KRAV OM SUPPLERENDE BESKYTTELSESSERTIFIKAT FOR NO NR. 2014017 AVSLAS Spc suppl protection certif: 2014017
2022-10-10	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: DAPAGLIFLOZIN OG FARMASOEYTISK AKSEPTABLE SALTER DERAV - FORLENGET SPC; REG. NO/DATE: 001-01 20121206 Spc suppl protection certif: 2022041 Filing date: 20221003
2023-07-10	MK1K	Patent expired